CytokeRatin 17 / KeRatin K17, Monoclonal Antibody

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 17; NC_000017.10 (39775692..39780882, complement). Location: 17q21.2

Monoclonal

IgG2b

E3

Mouse

E3 reacts with cytokeRatin 17 in basal layers of pseudo-stRatified and transitional epithelia.

Each vial contains 100 ug 1 mg/ml purified monoclonal antibody in PBS 0.02% sodium azide.

Store at 4 degree C, or in small aliquots at -20 degree C.

Small volumes of anti-KRT17 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

CytokeRatins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in Human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 - 7.8. The individual Human cytokeRatins are numbered 1 to 20. The various epithelia in the Human body usually express cytokeRatins which are not only characteristic of the type of epithelium, but also related to the degree of matuRation or differentiation within an epithelium. CytokeRatin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeRatin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays.

Cytoskeletal, Cell differentiation, Cytoskeleton

Flow Cytometry (FC), Immunocytochemistry (IHC), Immunohistochemistry (IHC) (frozen), Immunohistochemistry (IHC) (paraffin), Western Blot (WB)

E3 is suitable for immunoblotting, immunocytochemistry, immunohistochemistry on frozen and paraffin-embedded tissues and flow cytometry. Optimal antibody dilution should be determined by titRation; recommended range is 1:25 - 1:200 for flow cytometry, and for immunohistochemistry with avidin-biotinylated Horseradish peroxidase complex (ABC) as detection reagent, and 1:100 - 1:1000 for immunoblotting appliCations.

48,106 Da[Similar Products]

keratin 17

keratin, type I cytoskeletal 17; 39.1; CK-17; keratin-17; cytokeratin-17; OTTHUMP00000164770

Keratin, type I cytoskeletal 17

K1C17_HUMAN

This gene encodes the type I intermediate filament chain keratin 17, expressed in nail bed, hair follicle, sebaceous glands, and other epidermal appendages. Mutations in this gene lead to Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex. [provided by RefSeq]

K17: a type I cytoskeletal keratin. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. There are two types of cytoskeletal and microfibrillar keratin: type I (acidic; 40-55 kDa) [K9 to K20] and type II (neutral to basic; 56-70 kDa) [K1 to K8]. Both a basic and an acidic keratin are required for filament assembly. Generally associates with K6.

Protein type: Cytoskeletal

Chromosomal Location of Human Ortholog: 17q21.2

Cellular Component: cytoplasm; intermediate filament

Molecular Function: protein binding; MHC class II receptor activity; structural constituent of cytoskeleton; MHC class II protein binding

Biological Process: positive regulation of hair follicle development; epidermis development; hair follicle morphogenesis; positive regulation of translation; keratinization; intermediate filament organization; signal transduction; positive regulation of cell growth

Disease: Steatocystoma Multiplex; Pachyonychia Congenita 2

Guelstein, V. I., Tchypysheva, T. A., Ermilova, V. D., Litvinova, L. V., Troyanovsky, S. M., Bannikov, G. A. (1988). Monoclonal antibody mapping of keRatins 8 and 17 and of vimentin in normal Human mammary gland, benign tumors, dysplasias and breast cancer, Int J Cancer 42, 147-53. Troyanovsky, S. M., Guelstein, V. I., Tchipysheva, T. A., Krutovskikh, V. A., Bannikov, G. A. (1989). Patterns of expression of keRatin 17 in Human epithelia: dependency on cell position, J Cell Sci 93, 419-26. Wetzels, R. H., Kuijpers, H. J., Lane, E. B., Leigh, I. M., Troyanovsky, S. M., Holland, R., van Haelst, U. J., and Ramaekers, F. C. (1991). Basal cell-specific and hyperprolifeRation-related keRatins in Human breast cancer. Am J Pathol 138, 751-63. Moll, I., Moll, R. (1991). CompaRative cytokeRatin analysis of sweat gland ducts and eccrine poromas. Arch Dermatol Res. 283, 300-09. De Jong, E., van Vlijmen, I., van Erp, P., Ramaekers, F., Troyanowsky, S., Van de Kerkhof, P. (1991). Monoclonal anti-keRatin 17: A useful marker for anti-psoriatic therapies. Arch Dermatol Res 283, 480-82. Smedts, F., Ramaekers, F., Troyanovsky, S., Pruszczynski, M., Link, M., Lane, B., Leigh, I., and Vooijs, P. (1992). KeRatin expression in cervical cancer, Am J Pathol 141, 497-511. Wetzels, R. H., Schaafsma, H. E., Leigh, I. M., Lane, E. B., Troyanovsky, S. M., Wagenaar, S. S., Vooijs, G. P., and Ramaekers, F. C. (1992). Laminin and type VII collagen distribution in different types of Human lung carcinoma: correlation with expression of keRatins 14, 16, 17 and 18. Histopathology 20, 295-303. Smedts, F., Ramaekers, F., Troyanovsky, S., Pruszczynski, M., Robben, H., Lane, B., Leigh, I., Plantema, F., and Vooijs, P. (1992). Basal-cell keRatins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia. Am J Pathol 140, 601-12. Smedts, F., Ramaekers, F., Link, M., Lauerova, L., Troyanovsky, S., Schijf, C., and Vooijs, G. P. (1994). Detection of keRatin subtypes in routinely processed cervical tissue: impliCations for tumour classifiCation and the study of cervix cancer aetiology. Virchows Arch 425, 145-155. Demirkesen, C., Hoede, N., Moll, R. (1995). Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeRatins. J Cutan Pathol 22, 518-35. Moll, R., et al. (1995). Differenzierungsmarker bei gynäkologischen Tumoren: Methodische und diagnostische Aspekte. In: Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie. W Zuckschwerdt Verlag. Litvinov, S. V., van Driel, W., van Rhijn, C. M., Bakker, H. A., van Krieken, H., Fleuren, G. J., and Warnaar, S. O. (1996). Expression of Ep-CAM in cervical squamous epithelia correlates with an increased prolifeRation and the disappearance of markers for terminal differentiation. Am J Pathol 148, 865-75.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.